Growth pattern of colorectal liver metastasis as a marker of recurrence risk

Clinical and Experimental Metastasis

Volumn 32, Issue 4, 2015, Pages 369-381

  Eefsen, R L ^a,b,c   Vermeulen, P B ^d   Christensen, I J ^a,b   Laerum, O D ^a,b   Mogensen, M B ^c   Rolff, H C ^a,b,c   Van den Eynden, G G ^d   Hoyer Hansen G ^a,b   Osterlind, K ^c   Vainer, B ^e   Illemann, M ^a,b  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d GZA Hospitals St Augustinus   (Belgium)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Colon cancer; Desmoplasia; Hepatectomy; Histology; Liver metastasis; Prognosis; Survival

Indexed keywords

ADULT; AGED; CELL PROLIFERATION; COLORECTAL TUMOR; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER; LIVER NEOPLASMS; LIVER RESECTION; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84930899725     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9715-4     Document Type: Article

References (53)

1. Kemeny N (2007) Presurgical chemotherapy in patients being considered for liver resection. Oncologist 12:825–839
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254–259
3. Muratore A, Ribero D, Viganos L (2011) Epidemiology and natural history; surgical treatment of colorectal liver metastases. Springer, Milan, pp 1–6
4. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM (2010) Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 59:1383–1388
5. Grossmann I, Doornbos PM, Klaase JM, de Bock GH, Wiggers T (2014) Changing patterns of recurrent disease in colorectal cancer. Eur J Surg Oncol 40:234–239
6. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311–1319
7. Sorbye H (2014) Recurrence patterns after resection of liver metastases from colorectal cancer. Recent Results Cancer Res 203:243–252
8. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766
9. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van CE, Scheithauer W, Gruenberger T (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016
10. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van CE, Scheithauer W, Gruenberger T (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342
12. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019
13. Van CE, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haen G, Pinter T, Zaluski J, Zaluski J, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417
14. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van CE (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345
15. Van CE, Cervantes A, Nordlinger B, Arnold D (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 25:5643–5647
16. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77:1254–1262
17. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318
18. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:308–317
19. Vermeulen PB, Colpaert C, Salgado R, Royers R, Hellemans H, Van Den Heuvel E, Goovaerts G, Dirix LY, Van Marck E (2001) Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol 195:336–342
20. Van den Eynden GG, Bird NC, Majeed AW, Van LS, Dirix LY, Vermeulen PB (2012) The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin Exp Metastasis 29:541–549
21. Eefsen RL, Van den Eynden GG, Høyer-Hansen G, Brodt P, Laerum OD, Vermeulen PB, Christensen IJ, Wettergren A, Federspiel B, Willemoe GL, Vainer B, Osterlind K, Illemann M (2012) Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. J Oncol 2012:907971
22. Yamaguchi J, Komuta K, Matsuzaki S, Okudaira S, Fujioka H, Kanematsu T (2002) Mode of infiltrative growth of colorectal liver metastases is a useful predictor of recurrence after hepatic resection. World J Surg 26:1122–1125
23. Nagashima I, Oka T, Hamada C, Naruse K, Osada T, Muto T (1999) Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer. Am J Gastroenterol 94:739–743
24. Pinheiro RS, Herman P, Lupinacci RM, Lai Q, Mello ES, Coelho FF, Perini MV, Pugliese V, Andraus W, Cecconello I, D’Albuquerque LC (2014) Tumor growth pattern as predictor of colorectal liver metastasis recurrence. Am J Surg 207:493–498
25. Okano K, Yamamoto J, Kosuge T, Yamamoto S, Sakamoto M, Nakanishi Y, Hirohashi S (2000) Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathologic study of 152 first resection cases. Cancer 89:267–275
26. Nielsen K, Rolff HC, Eefsen RL, Vainer B (2014) The morphological growth patterns of colorectal liver metastases are prognostic for overall survival. Mod Pathol 27(12):1641–1648
27. Nystrom H, Naredi P, Berglund A, Palmqvist R, Tavelin B, Sund M (2012) Liver-metastatic potential of colorectal cancer is related to the stromal composition of the tumour. Anticancer Res 32:5183–5191
28. Lunevicius R, Nakanishi H, Ito S, Kozaki K, Kato T, Tatematsu M, Yasui K (2001) Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. J Cancer Res Clin Oncol 127:193–199
29. Couinaud C (1999) Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg 16:459–467
30. Vandeweyer D, Neo EL, Chen JW, Maddern GJ, Wilson TG, Padbury RT (2009) Influence of resection margin on survival in hepatic resections for colorectal liver metastases. HPB 11:499–504
31. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722
32. Angelsen JH, Horn A, Eide GE, Viste A (2014) Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol 12:127
33. Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, Punt CJ (2010) Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 103:159–164
34. Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobrero A, Douillard JY (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998–1003
35. Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 9:e1001216
36. Bancroft JD, Cook HC (1994) Connective tissue. In: Bancroft JD, Cook JC (eds) Manual of histological techniques and their diagnostic application. Churchill Livingstone, Edinburgh, pp 35–67
37. Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Danø K, Nielsen BS (2009) Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 124:1860–1870
38. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H (1999) Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 86:332–337
39. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K (2004) Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 91:327–333
40. Grossniklaus HE (2013) Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. JAMA Ophthalmol 131:462–469
41. Nakashima T, Kojiro M, Kawano Y, Shirai F, Takemoto N, Tomimatsu H, Kawasaki H, Okuda K (1982) Histologic growth-pattern of hepatocellular-carcinoma-relationship to orcein(hepatitis-B surface antigen)-positive cells in cancer-tissue. Hum Pathol 13:563–568
42. Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, Van Den Heuvel E, Harris AL, Jackson DG, Colpaert CG, van Marck EA, Dirix LY, Vermeulen PB (2004) Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 90:1429–1436
43. Terayama N, Terada T, Nakanuma Y (1996) Histologic growth patterns of metastatic carcinomas of the liver. Jpn J Clin Oncol 26:24–29
44. Knijn N, de Ridder JA, Punt CJ, de Wilt JH, Nagtegaal ID (2013) Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 63:149–156
45. Van den Eynden GG, van Dam PJ, Stroobants S, Dirix L, Vermeulen P (2014) Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 64:315–316
46. Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P (2013) The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis 30:457–470
47. van der Pool AE, Lalmahomed ZS, Ozbay Y, de Wilt JH, Eggermont AM, Jzermans JN, Verhoef C (2010) ‘Staged’ liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis 12:e229–e235
48. Ghiringhelli F, Hennequin A, Drouillard A, Lepage C, Faivre J, Bouvier AM (2014) Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study. Dig Liver Dis 46(9):854–858
49. Bova R, Kamphues C, Neuhaus P (2014) Puhl G [Impact of time of occurrence of liver metastases (synchronous vs. metachronous) on early postoperative outcome and long-term survival of colorectal cancer patients]. Zent Chir 139:220–225
50. Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai Y, Shenyong Z, Bo X, Li L, Xiangou P, Haohao L, Lechi Y, Tianshu L, Jia F, Xinyu Q, Jianmin X (2012) Outcome of patients with colorectal liver metastasis: analysis of 1613 consecutive cases. Ann Surg Oncol 19:2860–2868
51. Ng WW, Cheung YS, Wong J, Lee KF, Lai PB (2009) A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis. Asian J Surg 32:189–197
52. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH (2007) Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 14:786–794
53. Landreau P, Drouillard A, Launoy G, Ortega-Deballon P, Jooste V, Come L, Faivre J, Facy O, Bouvier AM (2014) Incidence and survival in late liver metastases of colorectal cancer. J Gastroenterol Hepatol 30(1):82–85